London, UK, and Hoofddorp, The Netherlands, 28 February 2017

PSR Orphan Experts, Ergomed’s rare disease specialist division, organises fundraiser to support Global Rare Disease Day® 2018

– Beach volleyball event to raise funds for children suffering from epidermolysis bullosa, a partly hereditary orphan incurable skin condition –

London, UK, and Hoofddorp, The Netherlands – 28 February 2018: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a specialised pharmaceutical services and drug development company, together with its rare disease subsidiary PSR Group…

London, UK, 12 December 2017

Ergomed expands its co-development pipeline with a multi-product partnership with Allergy Therapeutics for oral allergy immunotherapies

  • Ergomed to receive future tiered royalties for each product in addition to service fees
  • Further contribution to service growth plus upside from sustainable drug development
  • Ergomed’s extensive experience in conducting trials in allergy therapies led to new co development deal

London, UK – 12 December 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a…

London, UK, 23 October 2017

Ergomed’s first-in-class haemostat, PeproStat™, reports positive top-line results and meets key endpoints in Phase II study

–     Highly innovative blood free haemostat met the primary efficacy endpoint of superiority over standard of care in time to haemostasis with statistical significance across all surgery types tested

–     PeproStat was seen to be safe with no treatment related SAEs reported and no re-bleeding

–     PeproStat™ demonstrated superiority in…

London, UK, 28 September 2017

Acquisition of PSR Group BV, a specialist orphan drug CRO, for consideration of up to €5.7 million

Acquisition of PSR Group BV, a specialist orphan drug CRO, for consideration of up to €5.7 million


Placing to raise £2.9 million

  • Acquisition moves Ergomed towards leadership in orphan drug development services
  • PSR’s specialist orphan drug development business will complement Ergomed’s existing strong expertise in this area
  • PSR will expand Ergomed’s services…

London, UK, 27 September 2017

Ergomed Signs First Commercialisation Deal for Haemostatix Products

Boryung Pharmaceutical Co.Ltd licenses PeproStat and ReadyFlow for commercialisation in South Korea

Ergomed to receive an upfront and future milestone payments as well as double-digit share of product sales

Deal driven by British innovation in the treatment of surgical bleeding with multi-million dollar potential

London, UK / Seoul, Republic…

Page 1 of 1712345...10...Last »
Translate »